Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Last trade$10.55
Day change-$0.04 (-0.38%)
Day range$10.32 – $10.68
Volume164,156
Market cap$589M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$588.58M
Price / earnings
—
Price / book
11.98×
Price / sales
6.66×
EV / sales
6.25×
EV / EBITDA
-21.5×
Profitability
Earnings per share
-$0.51
Return on assets
-27.06%
Return on equity
-57.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.83×
Current ratio
5.04×
Quick ratio
4.72×
Cash ratio
3.84×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SGHT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.92M
$23.39M
$19.7M
$20.39M
$19.91M
$19.56M
$17.51M
$19.07M
Cost of revenue
$3.5M
$2.01M
$2.72M
$2.6M
$2.71M
$2.98M
$2.41M
$2.51M
Gross profit
$21.42M
$21.37M
$16.98M
$17.79M
$17.2M
$16.59M
$15.09M
$16.56M
Selling, general and administrative
$24.84M
$22.75M
$26.85M
$19.02M
$21.75M
$23.87M
$24.52M
$24.2M
Research and development
$2.71M
$2.51M
$2.55M
$2.44M
$3.35M
$4.39M
$4.43M
$4.29M
Total operating expenses
$27.55M
$25.26M
$29.39M
$21.46M
$25.1M
$28.25M
$28.95M
$28.49M
Operating income
-$6.13M
-$3.89M
-$12.41M
-$3.67M
-$7.91M
-$11.67M
-$13.86M
-$11.93M
Interest expense
-$1.31M
-$1.29M
-$1.27M
-$1.29M
-$1.31M
-$1.28M
-$1.26M
-$1.16M
Income before taxes
-$6.8M
-$4.42M
-$12.97M
-$4.15M
-$8.25M
-$11.9M
-$14.11M
-$11.81M
Income taxes
$11K
$28K
$11K
$8K
-$79K
$40K
$41K
$38K
Net income
-$6.81M
-$4.45M
-$12.98M
-$4.16M
-$8.17M
-$11.94M
-$14.15M
-$11.85M
Net income attributable to common shareholders
-$6.81M
-$4.45M
-$12.98M
-$4.16M
-$8.17M
-$11.94M
-$14.15M
-$11.85M
EBITDA
-$6.02M
-$3.79M
-$12.31M
-$3.56M
-$7.8M
-$11.54M
-$13.71M
-$11.75M
Basic earnings per share
-$0.12
-$0.08
-$0.24
-$0.08
-$0.16
-$0.23
-$0.28
-$0.23
Diluted earnings per share
-$0.12
-$0.08
-$0.24
-$0.08
-$0.16
-$0.23
-$0.28
-$0.23
Recent news
Company coverage with links to the original publishers.
Sight Sciences (SGHT) is highlighted as a momentum stock with a Zacks Rank #2 (Buy) rating and Momentum Style Score of B. The stock has outperformed its industry significantly, gaining 8.15% weekly, 32.36% monthly, and 41.45% annually. Recent earnings estimate revisions have been positive, with upward revisions for both current and next fiscal year estimates, suggesting continued momentum potential.
Sight Sciences reported Q3 2026 revenue of $24.92 million, up 25.2% year-over-year and beating consensus estimates by 6.46%. The company posted an EPS of -$0.12, matching expectations. Interventional Dry Eye revenue surged 1962.2% to $3.88 million, while Interventional Glaucoma revenue grew 6.7% to $21.05 million. Both segments exceeded analyst estimates. The stock has a Zacks Rank #3 (Hold) rating.
Sight Sciences (SGHT) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $24.92 million exceeding expectations by 6.46%. The company has outperformed the market by 18.8% year-to-date but received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
UnitedHealthcare updated its Glaucoma Surgical Treatments policy to cover OMNI Surgical System procedures for treating mild to moderate open-angle glaucoma, effective October 1, 2025, covering approximately 30 million lives.
A cost-utility analysis revealed that TearCare® System offers cost savings and better health utility compared to cyclosporine 0.05% for treating meibomian gland disease-associated dry eye disease, with $903 annual per-patient savings.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.